Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
648 results about "Cardiovascular disorder prevention" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Increasing the awareness of cardiovascular disorders, prevention of cardiovascular disorders in susceptible individuals or populations through promotion of health or with chemopreventive methods, and prevention of complications or after-effects of existing disease; this concept may overlap with CARDIOVASCULAR DISORDER EDUCATION.
Isolated antibody which specifically binds to PCSK9
Owner:PFIZER INC RINAT NEUROSCIENCE CORP
Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
InactiveUS6858383B2High serum cholesterol levelDecreased blood flowOrganic active ingredientsHydrolasesMetaboliteSphingolipid metabolism
Methods and compositions are disclosed that are useful for the prevention and / or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic / reperfusion damage in humans; and cardiovascular trauma. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that interfere with the production and / or biological activities of sphingolipids and their metabolites, particularly sphingosine (SPH) and sphingosine-1-phosphate (S-1-P). Also disclosed are methods for identifying and isolating therapeutic agents.
Owner:APOLLO ENDOSURGERY INC
Black soybean cake processing method
The invention provides a black soybean cake processing method. The processing comprises the steps that 1, black soybean powder, glutinous rice flour, rice flour, red dates, lily, sweet-scented osmanthus, the fruits of Chinese wolfberry, mint leaves, granulated sugar, sesame powder and palm oil are weighed; 2, the red dates, the lily, the sweet-scented osmanthus, the fruits of Chinese wolfberry and the mint leaves are heated and decocted; 3, the granulated sugar is heated to be dissolved; 4, the black soybean powder, the glutinous rice flour and the rice flour are mixed, and then mixed liquid and the palm oil are added in the mixture for high-temperature steaming; 5, the steamed cake is coated with the sesame powder in a rolling mode. The black soybean cake processing method has simple steps, the black soybean cake is crisp and delicious and makes people enjoy aftertaste, and black soybeans have rich nutrients and have the effects of promoting cholesterol metabolism, lowering blood lipid, preventing cardiovascular disease and the like. Meanwhile, due to the fact that the red dates, the lily, the sweet-scented osmanthus, the fruits of Chinese wolfberry, the mint leaves and the like are added in the formula, the black soybean cake has the effects of enriching yin, nourishing kidney, protecting the liver, nourishing the stomach, discharging toxicant, keeping beauty and the like.
Owner:江新祥
Soluble guanylate cyclase activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME CORP
Soluble guanylate cyclase activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME LLC
Ether compounds
InactiveUS6459003B1Reduce contentLower cholesterol levelsNervous disorderAntipyreticDyslipidemiaCholesterol
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
InactiveUS6673780B2Antibacterial agentsBiocideDyslipidemiaPeroxisome proliferator-activated receptor
The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
InactiveUS6881546B2High levelOrganic active ingredientsPeptide/protein ingredientsMetaboliteSphingolipid metabolism
Methods and compositions are disclosed that are useful for the prevention and / or treatment of cardiovascular and cardiac diseases and disorders, or damage resulting from surgical or medical procedures that may cause ischemic or ischemic / reperfusion damage in humans; and cardiovascular trauma. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that interfere with the production and / or biological activities of sphingolipids and their metabolites, particularly sphingosine (SPH) and sphingosine-1-phosphate (S-1-P). Also disclosed are methods for identifying and isolating therapeutic agents.
Owner:APOLLO ENDOSURGERY INC
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
The present invention relates to a method of treatment and / or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and / or marine oil to a patient. The present invention also relates to a composition for the treatment and / or prevention of these diseases.
Owner:AKER BIOMARINE ANTARCTIC
Ketone compounds and compositions for cholesterol management and related uses
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Adenoviral vector for inhibiting restenosis
InactiveUS6290949B1Prevent and lessen restenosisIncrease concentrationBiocideVectorsViral FunctionPercent Diameter Stenosis
Gene transfer vectors, especially adenoviral vectors, and synthetic vectors capable of emulating specific viral functions, that carry gene sequences capable of ameliorating or preventing the symptoms of cardiovascular disease are disclosed. Such methods can be used to treat restenosis, especially when incident to injury by angioplasty.
Owner:FRENCH BRENT A +2
Soluble guanylate cyclase activators
The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble guanylate cyclase activators
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Owner:MERCK SHARP & DOHME LLC
Soluble Guanylate Cyclase Activators
A compound having the structureuseful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.
Owner:MERCK SHARP & DOHME LLC
Ether compounds and compositions for cholesterol management and related uses
InactiveUS6713507B2Reduce contentLower cholesterol levelsAntibacterial agentsBiocideDyslipidemiaPeroxisome proliferator-activated receptor
Owner:ESPERION THERAPEUTICS
Compositions for treating or preventing cardiovascular disease
ActiveUS20050261257A1Avoid developmentImprove complianceBiocideKetone active ingredientsVascular calcificationRight-Sided
Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.
Owner:NATTOPHARMA
Preparation and use of Dendrobium nobile polysaccharide extract
InactiveCN101407557AQuality is easy to controlIncrease contentOrganic active ingredientsMetabolism disorderAlcoholMedicine
The invention provides a preparation method of dendrobium nobile polysaccharide extracts, which is realized by steps of degreasing, extracting, alcohol precipitating, protein removing, monose and oligosaccharide removing and purifying gel columns and the like. The polysaccharide content in the polysaccharide extract is more than 93 percent. The polysaccharide extract has remarkable oxidation prevention activity, can be combined with medicament excipients and carriers permitted by preparation agents, and can be applied in preparing medicaments or medicament combinations for treating and preventing cardiovascular diseases. The preparation method of the dendrobium nobile polysaccharide extracts is reasonable in design and convenient in operation.
Owner:ZHEJIANG UNIV
Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.
Owner:INOTECK PHARMA CORP
Nutritional vermicelli and making method thereof
InactiveCN102894279AGreat tasteMeet dietary requirementsFood preparationNutritive valuesAdditive ingredient
The invention provides a nutritional vermicelli and a making method thereof. Wheat flour is taken as the basic material of the nutritional vermicelli and oat powder, matcha powder, soybean meal, almond meal, yam meal, wheat gluten, drinking water and table salt are added. The nutritional vermicelli also comprises purple sweet potato powder, wolfberry powder and jujube powder. The making method of the nutritional vermicelli comprises the following steps: (1) kneading dough; (2) curing; (3) tabletting and cutting to strips; (4) drying; and (5) cutting off, measuring and packaging. Wheat flour is adopted as the main raw material and other raw materials with higher nutritive value are added. Compared with the traditional vermicelli, the nutritional vermicelli has rich nutritional ingredients, tastes good and effectively meets the requirements for dietary nutrition by people at present. As the nutritional vermicelli is rich in various microelements, the nutritional vermicelli is beneficial for lowering blood sugar level, reducing blood fat, preventing cardiovascular diseases and hypertension and improving immunity of human body.
Owner:宜垦(天津)农业制品有限公司
Chinese sausage containing dietary fibers and fish meat and production method thereof
The invention provides a Chinese sausage containing dietary fibers and fish meat and a production method thereof, which can make up for the shortage of the current sausage market. The technical scheme is as follows: the weight percentage of the dietary fibers is 2 percent to 20 percent, the weight percentage of the fish meat is 10 percent to 40 percent, the weight percentage of livestock meat is 30 percent to 70 percent, the weight percentage of seasoning is 5 percent to 15 percent, and the rest is water. The Chinese sausage has functions, such as preventing constipation and intestinal diseases, eliminating heavy metals and radicals in the body, preventing cardiovascular diseases, diabetes and breast cancer, preventing and treating gallstone, reducing blood pressure and enhancing the immunocompetence of the human body.
Owner:青岛农博农食品科技有限公司
Ketone compounds and compositions for cholesterol management and related uses
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Krill Oil Compositions
InactiveUS20080166420A1Low densityHigh densityCrustacean material medical ingredientsEster active ingredientsSignificant riskNiacin
The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined in one embodiment with niacin, and combined in an alternate embodiment with polymethoxylated flavones (PMFs), and combined in yet another embodiment with Cissus quadrangularis, and combined in a further embodiment with Gynostemma pentaphyllum.
Owner:SONES SCOTT F
Krill extracts for treatment of cardiovascular diseases
The present invention relates to a method of treatment and / or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and / or marine oil to a patient. The present invention also relates to a composition for the treatment and / or prevention of these diseases.
Owner:AKER BIOMARINE ANTARCTIC
Haematococcus extract preparation, and preparation method and use thereof
ActiveCN101978975AEasy to operateReduce energy consumptionSenses disorderNervous disorderMedicineBetaxanthins
The invention provides a haematococcus extract preparation, and a preparation method and use thereof. A haematococcus extract soft capsule provided by the invention comprises the contents of haematococcus extract and an oleic phase, wherein the astaxanthin content of the haematococcus extract is 2 to 20 percent (w / w); and the mass-to-volume ratio (g / mL) of astaxanthin in the haematococcus extract and the oleic phase is 1-10:100. The invention also provides the method for preparing the haematococcus extract soft capsules. Experiments show that the haematococcus extract soft capsule provided by the invention has stability remarkably superior to that of the haematococcus extract and conventional products and is of great importance to the application of the astaxanthin to antioxidation, the enhancement of immunity, the suppression of tumorigenesis, the prevention and treatment of cardiovascular disease, the prevention of skin aging and the maintenance of health of eyes and the central nervous system.
Owner:YUNNAN GREEN A BIOLOGICAL PROJECT
Krill oil compositions
InactiveUS20080166419A1Low densityHigh densityEster active ingredientsCrustacean material medical ingredientsSignificant riskNiacin
The present disclosure provides for novel krill oil-based compositions, method of administration and method of manufacture which provide for the treatment and prevention of cardiovascular disease, including the reduction of one or more significant risk factors involved with cardiovascular disease. The active ingredients of the composition include krill oil, combined in one embodiment with niacin, and combined in an alternate embodiment with polymethoxylated flavones (PMFs), and combined in yet another embodiment with Cissus quadrangularis.
Owner:SONES SCOTT F
Azaindole-derivatives as factor Xa inhibitors
The present invention relates to compounds of the formula Iwherein R0, R1, R2, R3, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and / or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and / or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and / or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
Owner:SANOFI AVENTIS DEUT GMBH
Ketone compounds and compositions for cholesterol management and related uses
ActiveUS20070155704A1Reduce contentLower cholesterol levelsAntibacterial agentsBiocideDyslipidemiaKetone
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
Owner:ESPERION THERAPEUTICS
Indazole-derivatives as factor Xa inhibitors
The present invention relates to a compound of the formula Iwherein J1, J2, R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and / or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and / or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and / or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
Owner:SANOFI AVENTIS DEUT GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com